|
🐜
|
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
51 auth.
S. Dreyer,
Rosie Upstill-Goddard,
Viola Paulus-Hock,
C. Paris,
E. Lampraki,
Eloise V. Dray,
B. Serrels,
G. Caligiuri,
S. Rebus,
Holly Brunton,
Richard Cunningham,
C. Nourse,
Ulla-Maja Bailey,
Marc D. Jones,
Kim Moran-Jones,
...
Derek W. Wright,
F. Duthie,
K. Oien,
Lisa Evers,
C. McKay,
Grant A. McGregor,
Aditi Gulati,
R. Brough,
I. Bajrami,
S. Pettitt,
Michele L Dziubinski,
J. Candido,
F. Balkwill,
S. Barry,
R. Grützmann,
L. Rahib,
A. Johns,
M. Pajic,
F. Froeling,
P. Beer,
E. Musgrove,
G. Petersen,
A. Ashworth,
M. Frame,
H. Crawford,
D. Simeone,
C. Lord,
D. Mukhopadhyay,
C. Pilarsky,
S. Cooke,
N. Jamieson,
J. Morton,
O. Sansom,
Peter Bailey,
A. Biankin,
D. Chang
|
6 |
2019 |
6
🐜
|
|
🐜
|
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
27 auth.
K. Van Baelen,
T. Geukens,
M. Maetens,
V. Tjan – Heijnen,
C.J. Lord,
S. Linn,
F. Bidard,
F. Richard,
W.W. Yang,
R.E. Steele,
S. Pettitt,
C. Van Ongeval,
M. De Schepper,
E. Isnaldi,
I. Nevelsteen,
...
A. Smeets,
K. Punie,
L. Voorwerk,
H. Wildiers,
G. Floris,
A. Vincent-Salomon,
P. Derksen,
P. Neven,
E. Senkus,
E. Sawyer,
M. Kok,
C. Desmedt
|
5 |
2022 |
5
🐜
|
|
🐜
|
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.
39 auth.
E. Harvey-Jones,
M. Raghunandan,
L. Robbez-Masson,
L. Magraner-Pardo,
T. Alaguthurai,
A. Yablonovitch,
J. Yen,
H. Xiao,
R. Brough,
J. Frankum,
F. Song,
J. Yeung,
T. Savy,
A. Gulati,
J. Alexander,
...
H. Kemp,
C. Starling,
A. Konde,
R. Marlow,
M. Cheang,
P. Proszek,
M. Hubank,
M. Cai,
J. Trendell,
R. Lu,
R. Liccardo,
N. Ravindran,
A. Llop-Guevara,
O. Rodríguez,
J. Balmaña,
N. Lukashchuk,
M. Dorschner,
L. Drusbosky,
I. Roxanis,
V. Serra,
S. Haider,
S. Pettitt,
C.J. Lord,
A. Tutt
|
4 |
2024 |
4
🐜
|
|
🐜
|
Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].
27 auth.
K. Van Baelen,
T. Geukens,
M. Maetens,
V. Tjan-Heijnen,
C. Lord,
S. Linn,
F. Bidard,
F. Richard,
W. W. Yang,
R. E. Steele,
S. Pettitt,
C. Van Ongeval,
M. De Schepper,
E. Isnaldi,
I. Nevelsteen,
...
A. Smeets,
K. Punie,
L. Voorwerk,
H. Wildiers,
G. Floris,
A. Vincent Salomon,
P. Derksen,
P. Neven,
E. Senkus,
E. Sawyer,
M. Kok,
C. Desmedt
|
0 |
2022 |
0
🐜
|
|
🐜
|
3P Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
12 auth.
J. Stewart,
J. Baxter,
D. Zatreanu,
R. Brough,
F. Song,
A. Konde,
...
D. Krastev,
J. Alexander,
R. Natrajan,
S. Pettitt,
S. Banerjee,
C. Lord
|
0 |
2022 |
0
🐜
|
|
🐜
|
405P HRD biomarkers in blood samples from BRCA1/BRCA2-associated advanced breast cancer (BC) patients (pts)
18 auth.
V. Serra,
H. Domenech,
S. Pettitt,
P. Proszek,
F. Pedretti,
A. H. Ropero,
A. R. Hernandez,
A. Suñol,
C. Viaplana,
J. D. Vivo,
...
S. Gutierrez-Enriquez,
M. Oliveira,
J. Mateo,
A. Prat,
C.J. Lord,
A. Tutt,
A. Llop-Guevara,
J. Balmaña
|
0 |
2024 |
0
🐜
|
|
🦁
|
435 (PB423): Persistence of BRCA1 and RAD51C methylation after neoadjuvant chemotherapy in high risk TNBC
20 auth.
S. Pettitt,
P. Proszek,
G. Torga,
A. Gulati,
A. Llop-Guevara,
P. Jank,
B. Felder,
A. Rodriguez,
S. Cooke,
I. Garcia-Murillas,
...
N. Ravindran,
T. Alaguthurai,
L. Jones,
Y. Roxanis,
V. Serra,
C. Denkert,
S. Loibl,
S. Haider,
C. Lord,
A. Tutt
|
0 |
2024 |
0
🦁
|
